Biotech Consultants

Innovative biotech products such as cell and gene therapies, CAR-T, monoclonal antibodies, and peptides are reshaping the future of healthcare. But success in China and Asia Pacific requires more than scientific innovation. However, successfully navigating China and Asia Pacific requires more than innovation. With evolving regulatory landscapes, diverse access pathways, and complex approval processes, companies need more than a local presence, they need a consulting partner with deep biotech expertise, regulatory foresight, and operational precision.

Cisema’s biotech consulting services support life sciences companies in navigating regulatory complexity, accelerating approvals, and optimizing commercialization across China and the Asia Pacific region. From early development through post-market compliance, we offer tailored solutions that drive success across at every stage of the biotech product lifecycle.

Biotech consultants
Biotech consultant
Biotech Consultants

Our services include:

Regulatory strategy and submission planning tailored for advanced therapies
Market access solutions aligned with real-world data and regional payer needs
End-to-end GxP quality and compliance support across the product lifecycle
Pharmacovigilance systems adapted to local requirements and global best practices

Whether you are developing novel therapies, initiating clinical trials, or expanding into Asia Pacific, our biotech consultants deliver solutions built for success in today’s complex regulatory landscape.

Discover Our Biotech Consulting Services

Biotech Product Development & Strategy

We help bring breakthrough therapies to market with confidence. Our development and strategy services are designed to establish strong regulatory foundations, mitigate development risks, and accelerate timelines to market.

Scientific and regulatory due diligence to assess feasibility and compliance
Gap analysis for cell and gene therapies, monoclonal antibodies, and peptides
Clinical development planning and regulatory strategy
Engagement with regulatory authorities
Scientific and technical writing for high-quality regulatory submissions

Health Economics & Market Access

We accelerate patient access and unlock commercial potential for innovative therapies. Our market access consultants help biotech companies navigate pricing and reimbursement frameworks, deliver strong value narratives, and align with health policy priorities across Asia Pacific.

Regulatory market intelligence
Payer engagement planning and stakeholder mapping
Health economics modeling and value dossier development
Pricing and reimbursement support
Competitive landscape analysis and HTA readiness

Regulatory Affairs for Biotech

Advance your biotech innovations with clarity and confidence. Cisema supports life sciences companies in navigating complex regulatory pathways for advanced therapies, from IND applications to marketing authorizations and post-market maintenance.

Strategic regulatory roadmaps and lifecycle planning
Regulatory authority engagement and meeting support
CTD dossier authoring, compilation, and submission
Country-specific adaptation and localization of global dossiers
Legal agent and representation services to ensure full compliance

Biotech Quality Management & Compliance

We ensure operational excellence and regulatory alignment. Our quality and compliance experts help biotech companies build and maintain robust quality systems, meet GxP standards, and prepare for inspections across China and Asia Pacific.

GxP audits and QMS/SOP reviews
Ingredient compliance and vendor audits
Pre-approval inspection readiness and support
Remediation planning and CAPA implementation

Pharmacovigilance for Biotech

We help safeguard patient safety while ensuring full regulatory compliance with confidence. Our pharmacovigilance services enable biotech companies to manage risk, maintain product safety, and meet stringent reporting obligations throughout clinical development and post-market phases.

Signal detection and safety risk management
Case processing and regulatory submissions
Clinical trial safety monitoring
PV audits and system readiness
Local QPPV services and post-market surveillance

Why Cisema?

Cisema brings together deep scientific expertise, regional regulatory insight, and over two decades of experience supporting novel therapies. Our biotech consultants are trusted by global innovators for their expertise in navigating Asia Pacific’s complex regulatory landscape.

We will help you:

build and execute region-specific strategies for advanced therapies
optimize development and submission timelines
align with HTA, payer, and policy expectations
ensure inspection readiness and regulatory compliance
expand market access and commercial reach

Whether you are advancing a gene therapy or commercializing a peptide, we support biotech success from discovery to delivery.

Pharma and healthcare expertise from the Cisema team

Other Industries We Support

In addition to pharmaceuticals and biotech, we offer consulting services across regulated industries, including medical devices, IVDs, cosmetics, health foods, veterinary products, and other industrial and consumer goods. Our team ensures tailored regulatory compliance strategies, regardless of product category or manufacturing model.

Medical Devices

In-Vitro Diagnostics

Cosmetics

Pharmaceuticals

Health Foods & Supplements

Veterinary Medicines & Products

Industrial Goods & Consumer Products

Aktuelle Einblicke

Mehr anzeigen

CDE Releases 2025 Annual Report on the Progress of Clinical Trials for New Drug Registration in China

Explore the latest data on China’s clinical research landscape, including record trial activity, shorter development timelines, and emerging R&D trends.

August 3, 2026
CDE Releases 2025 Annual Report on the Progress of Clinical Trials for New Drug Registration in China

China Targets 65 Drugs in Its 12th National Procurement Round

The 12th national VBP round introduces tighter quality, manufacturing, and IP requirements that pharmaceutical companies must meet to compete.

August 3, 2026
China Targets 65 Drugs in Its 12th National Procurement Round

China CDE Defines Classification Rules for Cell & Gene Therapy Drugs

New NMPA CDE guidelines define CTMP and GTMP boundaries, affecting development strategy, CMC planning, and regulatory engagement in China.

August 3, 2026
China CDE Defines Classification Rules for Cell & Gene Therapy Drugs

China's 2026 Essential Medicines Adds More Innovative Drugs

China's updated National Essential Medicines List expands access to innovative medicines, creating new opportunities and strategic considerations for pharmaceutical companies.

August 3, 2026
China's 2026 Essential Medicines Adds More Innovative Drugs
A middle-aged man with glasses is looking down thoughtfully as he pours medication or pills from a small white bottle with a yellow label into his open palm.

China NMPA Expands Priority Review for Chemical API Marketing Authorization Applications

China's NMPA expands priority review eligibility for chemical API marketing authorization applications, supporting domestic API production and drug supply.

August 3, 2026
China NMPA Expands Priority Review for Chemical API Marketing Authorization Applications
Chemical API Manufacturing

China Releases 2026 Anti-Corruption Priorities for Pharmaceutical Sales & Medical Services

China's 2026 enforcement priorities expand scrutiny of pharmaceutical sales, procurement, pricing, data security, and compliance across the healthcare sector.

August 3, 2026
China Releases 2026 Anti-Corruption Priorities for Pharmaceutical Sales & Medical Services
Zurück
Zurück

Get in Touch with Our Biotech Consultants

Speak to our biotech specialists to explore how our regulatory guidance, market access support, and operational expertise can help you bring innovative biotech therapies to market across China and Asia Pacific.

Angebot anfordern